FUTURE PLANS

Please refer to "Business – Our Development Strategies" for a detailed description of our future plans.

USE OF [REDACTED]

We estimate that we will receive net **[REDACTED]** from the **[REDACTED]** of approximately HK$**[REDACTED]**, after deducting **[REDACTED]** commissions, fees and estimated expenses payable by us in connection with the **[REDACTED]**, and assuming an **[REDACTED]** of HK$**[REDACTED]** per Share, which is the **[REDACTED]** of the indicative **[REDACTED]** stated in this document. If the **[REDACTED]** is set at **[REDACTED]** per Share, which is the **[REDACTED]** of the indicative **[REDACTED]**, the **[REDACTED]** from the **[REDACTED]** will increase by approximately HK$**[REDACTED]**. If the **[REDACTED]** is set at HK$**[REDACTED]** per Share, which is the **[REDACTED]** of the indicative **[REDACTED]**, the **[REDACTED]** from the **[REDACTED]** will decrease by approximately HK$**[REDACTED]** million.

We intend to apply these net **[REDACTED]** for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:

- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to the research and development, registration filings and commercialization of our Core Products, IHepcomf (艾馨甘) and IUrisure (艾光樂), as follows:
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to fund ongoing and planned research and development to further develop IHepcomf (艾馨甘), including
    - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to the research and development of the new indication of IHepcomf (艾馨甘) in MRD detection; For details, please refer to "Business – Our Product and Product Pipeline – IHepcomf (艾馨甘) – Our Core Product – Further Development Plans" in this document;
    - approximately **[REDACTED]**% or HK$**[REDACTED]** will be allocated to clinical development in other target markets, such as pivotal clinical trial in Europe to verify the clinical efficacy of IHepcomf (艾馨甘), with plans to submit the data from this clinical trial for EU Class C IVDR certification;
    - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to commercialization of IHepcomf (艾馨甘) which include expansion of our relevant sales force and conducting marketing activities to promote IHepcomf (艾馨甘), including hosting, sponsoring and attending in industry conferences and academic seminars in medical institutions, promoting awareness of liver cancer early detection with experts and KOLs, participating in the formulation of clinical guidelines, and improving our market penetration in public funded medical institutions. We plan to recruit additional 20 to 30 sales personnel responsible for China and overseas market in the coming three to five years. We plan to hold promotional events targeting the core end markets for IHepcomf (艾馨甘), namely liver diseases market and health management market. We plan to (a) sponsor and participate in approximately 30 provincial- and national-level industry conferences, such as the Annual Academic Conference of the Chinese Society of Hepatology and the Annual Academic Conference of the Chinese Society of Health Management; and (b) host 45–50 provincial-level symposiums on the application of methylation technology in liver cancer

detection, as well as 500 hospital-level seminars on the application of IHepcomf (艾馨甘). We also plan to participate in the formulation of the *Expert Consensus on the Application of Liver Cancer Detection Technology in Cancer Prevention Checkups* initiated by the National Cancer Center in 2026.

- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to the research and development, registration filings and commercialization of our Core Product IUrisure (艾光樂), including
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to advancing our candidate IUrisure (艾光樂), including (a) approximately **[REDACTED]**%, or HK$**[REDACTED]** will be allocated to research and development of the new indication of IUrisure (艾光樂) in MRD detection; and (b) approximately **[REDACTED]**%, or HK$**[REDACTED]** will be allocated to clinical development in other target markets, such as pivotal clinical trial in Europe to verify the clinical efficacy of IUrisure (艾光樂), with plans to use the data from this clinical trial to apply for EU Class C IVDR certification. For details, please refer to "Business – Our Product and Product Pipeline – IUrisure (艾光樂) – Our Core Product – Summary of Clinical Trial" in this document.
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be allocated to future commercialization of IUrisure (艾光樂) through promoting awareness of urothelial cancer early detection and increasing market penetration after the regulatory approval is granted. In the initial stage of the launch of IUrisure (艾光樂) , we will focus our promotional efforts on distributor channels and medical institutions, targeting the urology-related departments and clinical laboratories within medical institutions. In the coming three years, we plan to host 10 provincial and national-level promotional events to attract distributors for IUrisure (艾光樂). We plan to hold promotional events targeting our distributor channels and core end markets for IUrisure (艾光樂), namely urology market and health management market. From 2026 to 2030, we plan to (a) recruit additional sales personnel and to sponsor and participate in approximately 30 provincial- and national-level industry conferences and promotional conferences, such as the Annual Academic Conference of the Chinese Urological Association; and (b) host 45–50 provincial-level symposiums on the application of methylation technology in urothelial cancer detection, as well as 500 hospital-level seminars on the application of IUrisure (艾光樂). We also plan to participate in the formulation of *Expert Consensus on the Application of Bladder Cancer Detection Technology in Cancer Prevention Checkups* initiated by the National Cancer Center in 2027.
- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used to the development, registration filings and commercialization of our multiple pipeline products, as follows:
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for the development of the gastric cancer tests, including our IStomacomf (艾衛元) for gastric cancer. Specifically, we plan to (a) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** for the clinical trial of IStomacomf (艾衛元) and (b) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** to

participate in the formulation of guidelines and expert consensus for the early detection of gastric cancers. We plan to submit the clinical trial filing for IStomacomf (艾衛元) with the regulatory authority in the first half year of 2026.

- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for the development of the blood test for lung cancer, including our IPulmocomf (艾斐暢) for lung cancer. Specifically, we plan to (a) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** for the clinical trial of IPulmocomf (艾斐暢); and (b) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** to participate in the formulation of guidelines and expert consensus for the early detection of lung cancers. We plan to submit the clinical trial filing for IPulmocomf (艾斐暢) with the regulatory authority in the second half year of 2026.
- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for the development of the endometrial cancer test, including our IUterusure (艾宮樂) for endometrial cancer. Specifically, we plan to (a) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** for the clinical trial of IUterusure (艾宮樂); and (b) allocate approximately **[REDACTED]**%, or HK$**[REDACTED]** to participate in the formulation of guidelines and expert consensus for the early detection of endometrial cancers. We plan to submit the clinical trial filing for IUterusure (艾宮樂) in the second half year of 2027.
- approximately **[REDACTED]**%, or HK$**[REDACTED]** will be used for the development of pan-cancer tests. Specifically, we plan to further advance the R&D of the six-high-incidence-cancer combined detection panel and expand its pre-clinical validation. We plan to improve the traceability accuracy of our pan-cancer products and accelerate their regulatory submissions and commercialization of these products in China and other target markets.

- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for improving our general research and development capabilities and enhancing our technologies, as follows:
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used to update interactive development of iTBFinder technology platform, including enhancement of AI capabilities and upgrade of algorithm models, integrating a pre-trained large language model-based literature semantic fusion system to establish a closed loop process covering target discovery, validation and clinical data interpretation.
  - approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used to update automated detection equipment and development of key freezing reagents. Particularly, we are developing AMStation, a fully automated sample processing workstation that could process up to 60 fecal samples for pre-treatment and extract and transform 16 nucleic acid samples within approximately three hours, streamlining operations and supporting large-scale testing.
- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used to enhance the automation of our production facilities. We conduct all of the manufacturing process of our reagents and sample collection kits in-house and have manufacturing facilities located at Wuhan, China with current utilization rate of approximately 50%. For details of our manufacturing facilities, please refer to "Business – Manufacturing Infrastructure" in this document. We plan to establish fully automated production facilities that could significantly increase our production efficiency, which will further support our geographic expansion strategy. Specifically, we plan to construct a new

manufacturing facility in Wuhan with a planned total gross floor area of approximately 5,000 square metres with planned annual production capacity of 4 million testing kits. Site selection and preliminary planning are targeted to commence in the first quarter of 2027. The new facility is expected to be operational in early 2028.

- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for continued expansion and diversification of our product portfolio through potential acquisition or in-licensing of product candidates in the cancer detection field. We plan to pursue potential acquisition or in-licensing of product candidates for cancer detection that will complement our current pipeline and allow us to fully utilize our sales force and manufacturing capacity. Regarding potential acquisition, our potential targets are companies engaged in the development and manufacturing of automated in vitro diagnostic instruments, such as sample pre-processing systems, nucleic acid extraction and purification equipment, methylation conversion devices, fully automated molecular diagnostic systems, and AI interpretation terminals. We will prioritise enterprises with commercialised instruments that already hold medical device registration or filing certificates in China or CE/FDA certification abroad, enabling immediate integration with our products. We may also consider companies with products undergoing registration where regulatory risks are controllable and authorisation prospects are clear. Supported by strong R&D teams, proprietary automation patents, stable supply chains, with clear intellectual property ownership and no material compliance or product quality issues. According to Frost & Sullivan, there are more than 20 potential acquisition or in-licensing targets in China that satisfy the Company's criteria. For details, please refer to "Business – Our Development Strategies – Selectively pursue investment, acquisition or partnership opportunities to integrate industry resources" in this document. As of the Latest Practicable Date, we have not identified any specific acquisition or in-licensing target; and
- approximately **[REDACTED]**%, or HK$**[REDACTED]**, will be used for our working capital and other general corporate purposes.

The above allocation of the net **[REDACTED]** from the **[REDACTED]** will be adjusted on a pro rata basis in the event that the **[REDACTED]** is fixed at a higher or lower level compared to the **[REDACTED]** of the indicative **[REDACTED]** stated in this document. If the **[REDACTED]** is exercised in full, the **[REDACTED]** that we will receive will be approximately HK$**[REDACTED]**, assuming an **[REDACTED]** of HK$**[REDACTED]** per Share (being the **[REDACTED]** of the indicative **[REDACTED]**). In the event that the **[REDACTED]** is exercised in full, we intent to apply the additional **[REDACTED]** to the above purposes in the proportions stated above.

To the extent that our **[REDACTED]** are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations, bank loans and other borrowings.

To the extent that the **[REDACTED]** from the **[REDACTED]** are not immediately applied to the above purposes and to the extent permitted by applicable law and regulations, we intend to deposit the **[REDACTED]** into short-term interest-bearing accounts at licensed commercial banks and/or other authorised financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions). In such event, we will comply with the appropriate disclosure requirements under the Listing Rules.

We will issue an appropriate announcement if there is any material change to the above proposed use of **[REDACTED]**.